InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Apollomics Inc.

APLM Clue Score38
United States Fiscal year ends December CIK 0001944885
$21.50 -1.29% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $21.50 +720.61% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 26 Nov 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2020Revenue0.0Net income−74.8EPS, diluted−0.21Fiscal year 2021Revenue0.0Net income−94.8EPS, diluted−3.37Fiscal year 2022Revenue0.0Operating income1.0Net income−240.8EPS, diluted−844.95Fiscal year 2023Revenue0.0Net income−172.6EPS, diluted−231.99Fiscal year 2024Revenue0.0Net income−53.9EPS, diluted−52.80
FY2020FY2021FY2022FY2023FY2024
Revenue 0.0 0.0 0.0 0.0 0.0
Growth
Operating income n/a n/a 1.0 n/a n/a
Net income −74.8 −94.8 −240.8 −172.6 −53.9
Growth
EPS, diluted −0.21 −3.37 −844.95 −231.99 −52.80

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2020Operating cash flow−35.7Capital expenditure−0.1Free cash flow−35.8Dividends paid0.0Fiscal year 2021Operating cash flow−43.3Capital expenditure−0.1Free cash flow−43.4Dividends paid0.0Fiscal year 2022Operating cash flow−42.8Capital expenditure−0.4Free cash flow−43.2Dividends paid0.0Fiscal year 2023Operating cash flow−43.2Capital expenditure−0.0Free cash flow−43.2Dividends paid0.0Fiscal year 2024Operating cash flow−28.7Capital expenditure−0.0Free cash flow−28.8Dividends paid0.0
FY2020FY2021FY2022FY2023FY2024
Operating cash flow −35.7 −43.3 −42.8 −43.2 −28.7
Capital expenditure −0.1 −0.1 −0.4 −0.0 −0.0
Free cash flow −35.8 −43.4 −43.2 −43.2 −28.8
Growth
Dividends paid 0.0 0.0 0.0 0.0 0.0

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2020Cash130.6Shareholders’ equity−127.9Fiscal year 2021Cash46.7Shareholders’ equity−212.9Fiscal year 2022Cash32.7Shareholders’ equity−448.1Fiscal year 2023Cash32.1Shareholders’ equity41.2Fiscal year 2024Cash9.8Shareholders’ equity4.9
FY2020FY2021FY2022FY2023FY2024
Cash 130.6 46.7 32.7 32.1 9.8
Shareholders’ equity −127.9 −212.9 −448.1 41.2 4.9

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2024 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2020 31 Dec 2020 FY2021† 31 Dec 2021 FY2022† 31 Dec 2022 FY2023† 31 Dec 2023 FY2024 31 Dec 2024
Revenue and profit
0.0 0.0 0.0 0.0 0.0
Growth
31.4 35.6 35.5 34.2 24.6
n/a n/a 1.0 n/a n/a
Growth
−74.9 −94.8 −240.8 −172.6 −53.6
−0.1 0.0 0.0 0.0 0.3
−74.8 −94.8 −240.8 −172.6 −53.9
Growth
Per share
−0.21 −3.37 −844.95 −231.99 −52.80
−0.21 −3.37 −844.95 −231.99 −52.80
Growth
361.5 28.1 0.3 0.7 1.0
361.5 28.1 0.3 0.7 1.0
Growth −92.2% −99.0% +161.1% +37.1%

† The diluted share count jumps at 2021 and 2022 and 2023, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 5 of 5 years on file.